Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10245473 | 1.00 | TSHR (0.39) | TSHRLMNACNR1ADRA1ATDP1 | |
| SCHEMBL10246425 | 1.00 | TSHR (0.39) | TSHRLMNACNR1ADRA1ATDP1 | |
| SCHEMBL14266734 | 0.86 | ALDH1A1 (0.41) | LMNACNR1ADRA1ATDP1KDM4E | |
| SCHEMBL18893422 | 0.85 | TAS1R3 (0.30) | TAS1R3TAS1R1 | |
| SCHEMBL437046 | 0.82 | LMNA (0.38) | TSHRLMNACNR1ADRA1ATDP1 | |
| SCHEMBL10245268 | 0.80 | LMNA (0.50) | TSHRLMNACNR1ADRA1ATDP1 | |
| SCHEMBL6209012 | 0.80 | LMNA (0.50) | TSHRLMNACNR1ADRA1ATDP1 | |
| SCHEMBL13747070 | 0.80 | CA1 (0.31) | TAS1R3TAS1R1 | |
| SCHEMBL6209009 | 0.80 | LMNA (0.50) | TSHRLMNACNR1ADRA1ATDP1 | |
| SCHEMBL21790668 | 0.76 | CA2 (0.38) | TSHRTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20080058383-A1 | Androgen Receptor Modulators | KARO BIO AB (SE) | 2008-03-06 | — | — | US | disclosed |
| US-20080058383-A1 | Androgen Receptor Modulators | KARO BIO AB (SE) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058383-A1 | Androgen Receptor Modulators | NR5A1, ESRRA, AR | TSHR 200/4885LMNA 2695/4885CNR1 469/4885 |
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | TSHR 1567/4885LMNA 1467/4885CNR1 4356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.